Get started
Author

Cecilia Reyneri

Observed name: C. Reyneri
Institution: Human Technopole
ORCID: 0000-0002-9950-5468
Observed ORCID: 0000-0002-9950-5468
OpenAlex ID: A5077898802
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2023 · Alexander Waclawiczek, Aino-Maija Leppä, et al. · Cancer Discovery · 113
PDF
Data from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2023 · Alexander Waclawiczek, Aino-Maija Leppä, et al. · 1
Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition
2021 · Simon Renders, Aino-Maija Leppä, et al. · Blood · 1
Recurrent leukaemia stem cell states define the antigenic landscape of paediatric Acute Myeloid Leukaemia
2026 · Sina Kanannejad, Macarena Oporto Espuelas, et al. · bioRxiv (Cold Spring Harbor Laboratory)
3188 – Epigenetic Perturbation of Pediatric and Adult Acute Myeloid Leukemia as a New Approach to Target Leukemic Stem Cells
2026 · Cecilia Reyneri, Claudia D'Oria, et al. · Experimental Hematology
Supplementary Figure 5 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
PDF
Supplementary Figure 3 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
PDF
Supplementary Figure 4 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
PDF
Supplementary Figure 2 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
PDF
Supplementary Figure 7 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
PDF
Supplementary Figure 6 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
PDF
Supplementary Figure 1 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
PDF
Supplementary Tables 1-7 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Tables 1-7 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 3 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 5 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 2 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 1 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 4 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 6 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 7 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 7 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 1 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 5 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Supplementary Figure 2 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025 · Alexander Waclawiczek, Aino-Maija Leppä, et al.
Works count: 66
Citation count: 115
H-index: 1
I10-index: 1
Year
Topic
Type